PPH
VanEck Pharmaceutical ETF
PPH
VanEck Pharmaceutical ETF
-
NAV$120.07
as of November 17, 2026 -
YTD RETURNS18.45%
as of November 17, 2026 -
Total Net Assets$1.06B
as of November 17, 2026 -
Total Expense Ratio0.36%
-
Inception Date12/20/2011
Overview
Why PPH
- Highly Liquid CompaniesTracks the largest most liquid pharmaceutical companies
- Industry LeadersFavors established industry leaders with meaningful scale
- Global ScopeProvides exposure to U.S. and international equities for global industry representation
VanEck Pharmaceutical ETF (PPH®) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS® US Listed Pharmaceutical 25 Index (MVPPHTR), which is intended to track the overall performance of companies involved in pharmaceuticals, including pharmaceutical research and development as well a production, marketing and sales of pharmaceuticals.
Performance
Average Annual Total Returns* (%)
| 1 MO | 3 MO | YTD | 1 YR | 3 YR | 5 YR | 10 YR | LIFE 12/20/11 | |
|---|---|---|---|---|---|---|---|---|
| PPH (NAV) | 9.48 | 8.49 | 17.71 | 31.59 | 18.94 | 11.85 | 10.78 | 10.62 |
| PPH (Market Price) | 9.37 | 8.45 | 17.66 | 31.57 | 18.95 | 11.84 | 10.78 | 10.69 |
| MVIS US Listed Pharmaceutical 25 Index | 9.49 | 8.52 | 17.51 | 31.39 | 18.58 | 11.49 | 10.51 | 10.43 |
| 1 MO | 3 MO | YTD | 1 YR | 3 YR | 5 YR | 10 YR | LIFE 12/20/11 | |
|---|---|---|---|---|---|---|---|---|
| PPH (NAV) | -3.28 | 0.50 | 7.51 | 23.60 | 13.35 | 10.67 | 8.69 | 10.00 |
| PPH (Market Price) | -3.19 | 0.67 | 7.58 | 23.72 | 13.37 | 10.65 | 8.70 | 10.09 |
| MVIS US Listed Pharmaceutical 25 Index | -3.26 | 0.55 | 7.32 | 23.42 | 13.00 | 10.31 | 8.44 | 9.81 |
Holdings
Book a 15-minute call to learn more about the holdings.
Daily Holdings (%) as of 11/17/2026
Download XLS|
Ticker
|
Holding Name |
% of Net Assets
|
Market Value (US$)
|
|---|---|---|---|
|
LLY |
Eli Lilly & Co |
23.06 |
246,118,847 |
|
MRK |
Merck & Co Inc |
11.97 |
127,759,731 |
|
NVO |
Novo Nordisk A/S |
5.48 |
58,450,288 |
|
MCK |
Mckesson Corp |
5.05 |
53,843,348 |
|
PFE |
Pfizer Inc |
4.69 |
50,078,958 |
|
TEVA |
Teva Pharmaceutical Industries Ltd |
4.66 |
49,729,527 |
|
COR |
Cencora Inc |
4.47 |
47,683,872 |
|
BMY |
Bristol-Myers Squibb Co |
4.36 |
46,544,036 |
|
GSK |
Gsk Plc |
4.17 |
44,530,243 |
|
ABBV |
Abbvie Inc |
3.70 |
39,462,473 |
|
AZN |
Astrazeneca Plc |
3.68 |
39,273,352 |
|
NVS |
Novartis Ag |
3.67 |
39,140,251 |
|
SNY |
Sanofi Sa/France |
3.51 |
37,507,016 |
|
HLN |
Haleon Plc |
3.38 |
36,080,223 |
|
JNJ |
Johnson & Johnson |
3.31 |
35,285,928 |
|
TAK |
Takeda Pharmaceutical Co Ltd |
2.94 |
31,359,433 |
|
ZTS |
Zoetis Inc |
2.69 |
28,722,129 |
|
VTRS |
Viatris Inc |
1.58 |
16,834,604 |
|
JAZZ |
Jazz Pharmaceuticals Plc |
1.25 |
13,340,870 |
|
ELAN |
Elanco Animal Health Inc |
0.52 |
5,581,144 |
|
AXSM |
Axsome Therapeutics Inc |
0.49 |
5,253,108 |
|
CORT |
Corcept Therapeutics Inc |
0.43 |
4,550,626 |
|
DFTX |
Definium Therapeutics Inc |
0.34 |
3,661,688 |
|
OGN |
Organon & Co |
0.27 |
2,847,179 |
|
PRGO |
Perrigo Co Plc |
0.10 |
1,106,447 |
|
-USD CASH- |
-- |
-0.00 |
-5,085 |
|
-- |
Other/Cash |
0.23 |
2,482,135 |
Portfolio
- Market Capitalization (%)
- Currency Exposure (%)
- Sector Weightings (%)
- Country Weightings (%)
Sector Weightings (%) as at 10/31/2026
-
Sector
% of Net Assets -
Health Care
99.90 -
Other/Cash
0.10
Country Weightings (%) as at 10/31/2026
-
Country
% of Net Assets -
United States
68.70 -
United Kingdom
11.27 -
Denmark
5.42 -
Israel
4.63 -
Switzerland
3.73 -
France
3.30 -
Japan
2.86 -
Other/Cash
0.10
Fees
Distributions
as of 11/17/2026
Quarterly
1.57%
1.20%
1.78%
Team
Resources
Regulatory Information
-
Name
Frequency - Annually
- Annually
-
Statement of Additional Information (SAI)
Annually - Annually
- Annually
Fund Documents
-
Name
Frequency -
PPH Fund Profile: A Perfect Prescription for Growth Portfolios
- Daily
-
VanEck Tax Information & Distributions
Annually -
NAV & Premium/Discount History
Daily - Annually
Thought Leadership
-
Name
Frequency